Business
Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment
Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), and Hygtia Therapeutics Co., Ltd., (Hygtia Therapeutics), today announced a co-development collaboration agreement for Insilico's ISM8969 program. Through the partnership, the two parties aim to accelerate the global advancement of ISM8969—an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.
About this update from Insilico Medicine Cayman Topco
[{"type":"list","items":[{"val":[{"type":"text","content":"Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and Insilico is eligible to receive up to USD 66 million in upfront and milestone payments.","length":376,"tagName":"p"}]},{"val":[{"type":"text","content":"Insilico will lead the IND submission and Phase 1 clinical trial of ISM8969, after which Hygtia Therapeutics will take responsibility for further clinical development, regulatory filings, and commercialization.","length":210,"tagName":"p"}]},{"val":[{"type":"text","content":"ISM8969, an orally available, brain penetrant NLRP3 inhibitor discovered using Insilico's generative AI platform Chemistry42, has demonstrated strong efficacy, favorable safety, and robust blood-brain barrier (BBB) penetration in preclinical studies.","length":259,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":845,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., Jan. 20, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), and Hygtia Therapeutics Co., Ltd., (Hygtia Therapeutics), today announced a co-development collaboration agreement for Insilico's ISM8969 program. Through the partnership, the two parties aim to accelerate the global advancement of ISM8969—an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.","length":533,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Insilico grants Hygtia Therapeutics 50% worldwide rights to research, develop, register, manufacture, and commercialize ISM8969. In return, Insilico is eligible to receive upfront and milestone payments totaling up to USD$66 million, including an initial upfront payment of USD$10 million expected within 30 days of the agreement's effective date.","length":385,"tagName":"p"},{"type":"text","content":"Reflecting the joint commitment to the program's success, Insilico will lead the initial clinical development, including IND submission and execution of the Phase 1 clinical trial for the Parkinson's ...